Study of Health in Pomerania

Last updated

The Study of Health in Pomerania (SHIP) is a population-based epidemiological study consisting of two independent cohorts (SHIP and SHIP-TREND). The SHIP investigates common risk factors, subclinical disorders and manifest diseases with highly innovative non-invasive methods in the high-risk population of northeast Germany. The study is not interested in one specific disease. The SHIP study´s main aims include the investigation of health in all its aspects and complexity involving the collection and assessment of data relevant to the prevalence and incidence of common, population-relevant diseases and their risk factors.

Contents

Design

study region of the SHIP Study region of the SHIP.jpg
study region of the SHIP

The aims of both studies are: (i) investigation of the long-term progression of subclinical findings, their determinants and prognostic values (SHIP-2); (ii) analysis of the secular trend of subclinical and overt diseases and their determinants in a high-risk population (SHIP-TREND vs SHIP-0); and (iii) assessment of the prevalence of subclinical findings (SHIP-TREND).

For SHIP-0, a sample of 7008 women and men aged 20 to 79 years was drawn in the cities of Greifswald, Stralsund and Anklam and 29 communities in the surrounding region which is part of West Pomerania, a region in the northeast of Germany, adjacent to the Baltic Sea in the north and to the Polish border in the east. West Pomerania is the north-eastern part of Mecklenburg-Vorpommern, one of the 16 federal German states.

A separate stratified random sample of 8016 adults aged 20–79 years was drawn for SHIP-TREND in the same area.

Currently, data are collected for the second examination follow-up of the first SHIP cohort (SHIP-2) and baseline examinations of the second SHIP cohort (SHIP-TREND).

SHIP-0: Data collection was conducted between October 1997 and May 2001.

SHIP-1 follow-up examination: SHIP-0 participants were invited again. The first 5-year-follow-up was conducted between October 2002 and September 2006.

SHIP-2 follow-up examination: The 11-year follow-up has started in June 2008 and was completed in autumn 2012.

SHIP-Trend-0: A new sample was drawn for a new cohort, which was examined between September 2008 and summer 2012.

Data collection

The following table shows all the instruments which are integrated in the SHIP examination.

instruments integrated in the examination program of SHIP Instruments SHIP 27.11.2010.JPG
instruments integrated in the examination program of SHIP
self-report questionnaires integrated in SHIP Questionnaires 27102010.JPG
self-report questionnaires integrated in SHIP
instruments integrated in the interviews of SHIP Instruments interviews SHIP.JPG
instruments integrated in the interviews of SHIP

Previous results

The West Pomeranian population indicate a high prevalence of common risk factors and diseases. Especially overweight and obesity are more prevalent than in other German regions. Gallstone diseases are very common and 30% of all adults suffer from hepatic steatosis. The prevalence of arterial hypertension and left ventricular hypertrophy is much higher in the West Pomeranian adult population. In the Northeast of Germany nearly 50% - 60% indicate these diseases.

Magnetic resonance imaging (MRI)

SHIP is the first population based cohort study worldwide which includes whole-body MRI. The aims of the following main whole body-MRI study are:

standardized whole-body MR imaging protocol for all participants of SHIP MRI Protocol.JPG
standardized whole-body MR imaging protocol for all participants of SHIP

(1)To provide prevalence estimates for different MR findings in a general adult population.

(2)To establish population-based MRI reference parameters for various organs and organ parts such as left and right ventricular size or volume of liver, spleen, kidney, prostate, [1] and brain structures . Clinical MR reference parameters currently in use were derived from small, nonrepresentative samples and are thus prone to selection bias.

(3)To correlate MR findings with clinical examination results, metabolomic and genome-wide analysis in order to help elucidate the complex associations that exist between risk factors and diseases.

MRI Protocol

Additionally to the standard whole-body MRI protocol (right figure) men have the option to undergo contrast-enhanced cardiac MRI and MR angiography and women cardiac MRI and MR mammography. Participants with a drug allergy or allergy to any kind of contrast agent are excluded from the contrast-enhanced modules and only undergo standard protocol.

Assessment of Pathological Findings and Management

Two trained radiologists review all scans independently to evaluated images for presence or absence of pathological findings. In case of a difference between the two observer a third reading is performed to reach a consensus on the discrepant finding.

Pathological findings are categorized using the method chosen by Bryan et al. for the Cardiovascular Health Study. This method classifies all findings into 4 basic categories. The management of pathological findings and communication with study participants are defined in a standardized protocol accepted by the local ethics committee. Participants with category IV findings are immediately transferred to a clinical specialist. Cases with positive findings of category II and III are referred to an Advisory Board established when the study began. and having as permanent members specialists from medical, surgical, neurological, epidemiological and radiological departments. Upon presentation of cases they reach a consensus about whether to recommend further clinical work-up or not. Participants in whom relevant findings are made get informed about the abnormality and recommendation of the Advisory Board.

Ship-Legende

SHIP-LEGEND stands for Life-Events and Gene-Environment interaction in Depression; its main aim is the identification of genetic factors which interact with stress and traumatic events to increase the risk of major depressive disorders. SHIP is the basis for this research. Between July 2007 and August 2010 n=2393 probands were interviewed. The interviewer assessed stress, traumas and strains in childhood and adulthood of the probands. Additionally diagnostic interviews were performed to diagnose current and lifetime mental disorders (DSM-IV). A broad range of questionnaires were administered to assess e.g. alexithymia (Toronto Alexithymia Scale 20), aversive childhood conditions (Childhood Trauma Questionnaire), depression (Beck Depression Inventory-2), resilience (RS-25) and personality traits (NEO-FFI).

Funding

SHIP is funded by following institutions: Federal Ministry of Education and Research, Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, Federal Ministry of Nutrition, Agriculture and Consumer’s Safety, German Research Foundation, Competence Network Heart Failure, Competence Network Diabetes, German Asthma and COPD Network, Genopathomik, Alfried Krupp von Bohlen und Halbach Foundation, Alexander v. Humboldt Foundation, Leibniz Society, Siemens AG, Health Care Sector (Erlangen, Germany), Pfizer Pharma GmbH (SBU Endocrinology and Ophthalmology; Berlin Germany), Novo Nordisk (Mainz, Germany), Data Input GmbH (Darmstadt, Germany), GABA International AG (Therwil, Switzerland), Imedos Systems (Jena, Germany) and Heinen and Löwenstein (Bad Ems, Germany).

Publications

Related Research Articles

<span class="mw-page-title-main">Androgen insensitivity syndrome</span> Medical condition

Androgen insensitivity syndrome (AIS) is a difference in sex development involving hormonal resistance due to androgen receptor dysfunction.

<span class="mw-page-title-main">Resistin</span> Mammalian protein found in Homo sapiens

Resistin also known as adipose tissue-specific secretory factor (ADSF) or C/EBP-epsilon-regulated myeloid-specific secreted cysteine-rich protein (XCP1) is a cysteine-rich peptide hormone derived from adipose tissue that in humans is encoded by the RETN gene.

<span class="mw-page-title-main">Partial androgen insensitivity syndrome</span> Medical condition

Partial androgen insensitivity syndrome (PAIS) is a condition that results in the partial inability of the cell to respond to androgens. It is an X linked recessive condition. The partial unresponsiveness of the cell to the presence of androgenic hormones impairs the masculinization of male genitalia in the developing fetus, as well as the development of male secondary sexual characteristics at puberty, but does not significantly impair female genital or sexual development. As such, the insensitivity to androgens is clinically significant only when it occurs in individuals with a Y chromosome. Clinical features include ambiguous genitalia at birth and primary amenhorrhoea with clitoromegaly with inguinal masses. Müllerian structures are not present in the individual.

<span class="mw-page-title-main">Steroid 11β-hydroxylase</span> Protein found in mammals

Steroid 11β-hydroxylase, also known as steroid 11β-monooxygenase, is a steroid hydroxylase found in the zona glomerulosa and zona fasciculata of the adrenal cortex. Named officially the cytochrome P450 11B1, mitochondrial, it is a protein that in humans is encoded by the CYP11B1 gene. The enzyme is involved in the biosynthesis of adrenal corticosteroids by catalyzing the addition of hydroxyl groups during oxidation reactions.

<span class="mw-page-title-main">HESX1</span> Protein-coding gene in the species Homo sapiens

Homeobox expressed in ES cells 1, also known as homeobox protein ANF, is a homeobox protein that in humans is encoded by the HESX1 gene.

<span class="mw-page-title-main">SRD5A2</span> Protein-coding gene in the species Homo sapiens

The human gene SRD5A2 encodes the 3-oxo-5α-steroid 4-dehydrogenase 2 enzyme, also known as 5α-reductase type 2 (5αR2), one of three isozymes of 5α-reductase.

Mechanography is a medical diagnostic measurement method for motion analysis and assessment of muscle function and muscle power by means of physical parameters. The method is based on measuring the variation of the ground reaction forces over the time for motion patterns close to typical every day movements. From these ground reaction forces centre of gravity related physical parameters like relative maximum forces, velocity, power output, kinetic energy, potential energy, height of jump or whole body stiffness are calculated. If the ground reaction forces are measured separately for left and right leg in addition body imbalances during the motions can be analysed. This enables for example to document the results of therapy. The same methodology can also be used for gait analysis or for analysis of stair climbing, grip strength and Posturography. Due to the utilization of every-day movements reproducibility is high over a wide age range

<span class="mw-page-title-main">IGFBP2</span> Protein-coding gene in the species Homo sapiens

Insulin-like growth factor-binding protein 2 is a protein that in humans is encoded by the IGFBP2 gene.

<span class="mw-page-title-main">Thyroid hormone receptor beta</span> Protein-coding gene in the species Homo sapiens

Thyroid hormone receptor beta (TR-beta) also known as nuclear receptor subfamily 1, group A, member 2 (NR1A2), is a nuclear receptor protein that in humans is encoded by the THRB gene.

<span class="mw-page-title-main">HPGD</span> Protein-coding gene in humans

Hydroxyprostaglandin dehydrogenase 15-(NAD), also called 15-hydroxyprostaglandin dehydrogenase [NAD+], is an enzyme that in humans is encoded by the HPGD gene.

<span class="mw-page-title-main">IGFBP7</span> Protein-coding gene in the species Homo sapiens

Insulin-like growth factor-binding protein 7 is a protein that in humans is encoded by the IGFBP7 gene. The major function of the protein is the regulation of availability of insulin-like growth factors (IGFs) in tissue as well as in modulating IGF binding to its receptors. IGFBP7 binds to IGF with low affinity compared to IGFBPs 1-6. It also stimulates cell adhesion. The protein is implicated in some cancers.

<span class="mw-page-title-main">PROP1</span> Human gene

Homeobox protein prophet of PIT-1 is a protein that in humans is encoded by the PROP1 gene.

<span class="mw-page-title-main">TSHB</span> Protein-coding gene in the species Homo sapiens

Thyroid stimulating hormone, beta also known as TSHB is a protein which in humans is encoded by the TSHB gene.

<span class="mw-page-title-main">Complete androgen insensitivity syndrome</span> Intersex condition that results in a phenotypic female

Complete androgen insensitivity syndrome (CAIS) is an AIS condition that results in the complete inability of the cell to respond to androgens. As such, the insensitivity to androgens is only clinically significant when it occurs in individuals who are exposed to significant amounts of testosterone at some point in their lives. The unresponsiveness of the cell to the presence of androgenic hormones prevents the masculinization of male genitalia in the developing fetus, as well as the development of male secondary sexual characteristics at puberty, but does allow, without significant impairment, female genital and sexual development in those with the condition.

Cyril Y. Bowers, M.D., emeritus professor of medicine at Tulane University School of Medicine, attended medical school at the University of Oregon and did an internship at the University of Washington. He then studied biochemistry at Cornell University and attended the postgraduate school of medicine at the University of Pennsylvania. From 1961-2004 he was the director of the Section of Endocrinology & Metabolism in the department of medicine at Tulane University School of Medicine. Bowers has served on the editorial board of several endocrine journals, was a member of the National Institute of Diabetes and Digestive and Kidney Diseases Study Section for eight years and has written over 400 articles in peer-reviewed journals, including chapters in books and over 200 abstracts.

<span class="mw-page-title-main">Mild androgen insensitivity syndrome</span> Medical condition

Mild androgen insensitivity syndrome (MAIS) is a condition that results in a mild impairment of the cell's ability to respond to androgens. The degree of impairment is sufficient to impair spermatogenesis and / or the development of secondary sexual characteristics at puberty in males, but does not affect genital differentiation or development. Female genital and sexual development is not significantly affected by the insensitivity to androgens; as such, MAIS is only diagnosed in males. The clinical phenotype associated with MAIS is a normal male habitus with mild spermatogenic defect and / or reduced secondary terminal hair.

<span class="mw-page-title-main">Leonid Poretsky</span> American endocrinologist

Leonid Poretsky is a Russian-born American endocrinologist. His research interests include mechanisms of insulin action in the ovary, endocrinological aspects of AIDS, and clinical outcomes in diabetes. He has authored over 150 publications and has served on the National Institutes of Health's review committees and on the editorial boards of the Journal of Clinical Endocrinology and Metabolism and other endocrine journals.

<span class="mw-page-title-main">Fertile eunuch syndrome</span> Medical condition

The fertile eunuch syndrome or Pasqualini syndrome is a cause of hypogonadotropic hypogonadism caused by a luteinizing hormone deficiency. It is characterized by hypogonadism with spermatogenesis. Pasqualini and Bur published the first case of eunuchoidism with preserved spermatogenesis in 1950 in la Revista de la Asociación Médica Argentina. The hypoandrogenism with spermatogenesis syndrome included:

Robert A. Vigersky is an American endocrinologist, Professor of Medicine at the Uniformed Services University of the Health Sciences, and pioneering military healthcare professional. His career has focused on diabetes care, research, and advocacy, publishing 148 papers and 118 abstracts in the fields of reproductive endocrinology and diabetes. Vigersky is a retired colonel in the U.S. Army Medical Corps, past president of the Endocrine Society, and recipient of the General Maxwell R. Thurman Award. He served in Iraq, Korea and Germany and is the recipient of military awards including the U.S. Army's Legion of Merit in 2009.

<span class="mw-page-title-main">Jostel's TSH index</span>

Jostel's TSH index, also referred to as Jostel's thyrotropin index or Thyroid Function index (TFI), is a method for estimating the thyrotropic function of the anterior pituitary lobe in a quantitative way. The equation has been derived from the logarithmic standard model of thyroid homeostasis. In a paper from 2014 further study was suggested to show if it is useful, but the 2018 guideline by the European Thyroid Association for the diagnosis of uncertain cases of central hypothyroidism regarded it as beneficial. It is also recommended for purposes of differential diagnosis in the sociomedical expert assessment.

References

  1. Habes M, Schiller T, Rosenberg C, Burchardt M, Hoffmann W (2013). "Automated prostate segmentation in whole-body MRI scans for epidemiological studies". Physics in Medicine and Biology . 58 (17): 5899–5915. Bibcode:2013PMB....58.5899H. doi:10.1088/0031-9155/58/17/5899. PMID   23920310. S2CID   9267032.